A Phase 3, Multicenter, Randomized, Controlled, Open-Label Clinical Trial of Aglatimagene Besadenovec (CAN-2409) Plus Prodrug and Pembrolizumab Versus Docetaxel for Stage IV Non-Squamous Non-Small Cell Lung Cancer Progressing on Pembrolizumab-based Treatment

This phase III trial compares the effect of the combination of aglatimagene besadenovec and pembrolizumab versus standard of care docetaxel chemotherapy for the treatment of stage IV non-squamous, non-small cell lung cancer. Aglatimagene besadenovec is a replication-deficient adenoviral vector encoding the herpes simplex virus thymidine kinase (HSV-tk) gene. When combined with an oral prodrug (valacyclovir), injection of aglatimagene induces targeted tumor cell death and stimulates a systemic immune response. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving aglatimagene with pembrolizumab is more effective at treating patients with stage IV non-squamous, non-small cell lung cancer than standard chemotherapy.

开始日期2026-06-15

申办/合作机构

Candel Therapeutics, Inc.

NCT07332000

/ Recruiting临床2期

A Biomarker Study in Men With Localized, Favorable, Intermediate-risk Prostate Cancer Treated With Aglatimagene Besadenovec

Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation therapy (EBRT).

开始日期2025-10-30

申办/合作机构

Candel Therapeutics, Inc.

NCT04495153

/ Active, not recruiting临床2期

CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients

The purpose of this clinical trial is to evaluate the effects of adding CAN-2409 + prodrug for stage III/IV NSCLC patients who are on standard of care first line immune checkpoint inhibitor (ICI) treatment with evidence that the clinical response is inadequate. CAN-2409 is a viral immunotherapy approach that induces tumor-infiltrating T-cells and a consequent PD-L1 up-regulation. A combination of CAN-2409 added to standard of care (SOC) checkpoint inhibitors may lead to improved long-term outcomes for patients with NSCLC who have suboptimal response to ICI therapy.

开始日期2020-10-13

申办/合作机构

Candel Therapeutics, Inc.

[+1]

100 项与 Aglatimagene besadenovec 相关的临床结果

登录后查看更多信息

100 项与 Aglatimagene besadenovec 相关的转化医学

登录后查看更多信息

100 项与 Aglatimagene besadenovec 相关的专利（医药）

登录后查看更多信息

项与 Aglatimagene besadenovec 相关的文献（医药）

2026-02-01·JTCVS open

Neoadjuvant intratumoral immune stimulation using gene-mediated cytotoxic immunotherapy for resectable non−small cell lung cancer: 5-Year outcomes

Article

作者: Jarrar, Doraid ; Aguilar-Cordova, Estuardo ; Predina, Jarrod ; Pechet, Taine ; Singhal, Sunil ; Niemeyer, Emma ; Albelda, Steven ; Rekhtman, David ; Nichols, William Garrett ; Aicher, Aidan ; Haas, Andrew ; Aguilar, Laura ; Kucharczuk, John ; Eisinger, Ella ; Davis, Christiana

Objectives:

Safety and immunologic priming using neoadjuvant, intratumoral gene-mediated cytotoxic immunotherapy (GMCI) has been established in a phase 1 clinical trial involving patients with resectable non-small cell lung cancer (NSCLC). Here we examine long-term clinical outcomes of this cohort and compare the results with a comparable contemporaneous control group.

Methods:

We performed a retrospective review of a prospective database involving our trial cohort. We then identified comparable patients in a ratio of 5:1 considering pathologic stage, histology, resection extent, and age. Kaplan-Meier curves were generated. Differences in disease-free and overall survival were measured by log-rank test.

Results:

Intratumoral GMCI was delivered to 12 patients with NSCLC by endobronchial ultrasound (n = 11) or video-assisted thoracic surgery (n = 1). Among patients receiving GMCI and control patients, more than 70% had stage II or stage III disease. Median follow-up for the surviving patients enrolled was 6.0 years (interquartile range, 5.2-6.7 years). Median diseases-free survival was significantly increased among patients receiving GMCI relative to control (2.4 years vs 1.0 year; P = .04). Median OS in the GMCI group was not reached (8 of 12 patients remain alive) versus 3.0 years in controls and was significant by log-rank at 2-7 years (P = .013-.035).

Conclusions:

Neoadjuvant immune stimulation induces local and systemic immune activation, is safe when combined with modern systemic therapies, and may confer long-term oncologic advantages. These data provide a foundation for additional trials exploring intratumoral immunotherapy for patients with NSCLC, especially in conjunction with immune checkpoint inhibitors.

2025-12-01·CHILDS NERVOUS SYSTEM

The effect of oncolytic virotherapy on pediatric brain tumor- a systematic review

Review

作者: Keerthana Veluswami ; Jonathan Roy Varghese ; Thirumalaivasan Dhasakeerthi ; Hari Vorappan Manickavelan ; Mansi Agrawal ; Gurunathan Srinivasan ; Praveen Nandha Kumar Pitchan Velammal

BACKGROUND:

Childhood mortality remains high among pediatric brain tumor (PBT) patients, and current treatments like surgery, chemotherapy, and radiotherapy have limitations. Oncolytic viral therapy (OVT) has emerged as a promising strategy in cancer treatment, including pediatric brain tumors. This study evaluates the clinical evidence on the use of OVT in PBT.

METHODS:

A systematic review was conducted following PRISMA guidelines, collecting clinical trial data up to December 2023 from English-language publications. Key search terms included "clinical trial," "oncolytic viruses," "glioma," "glioblastoma," "pediatric brain tumors," and "oncolytic virotherapy." Data on patient characteristics, interventions, survival outcomes, and adverse events were extracted by two independent researchers.

RESULTS:

Four clinical trials involving 40 pediatric patients (median age 14.5 years) with malignant gliomas were identified. Oncolytic agents studied included HSV G-207, DNX-2401, AdV-tk, and Lerapolturev. Reported tumor types included glioblastoma, diffuse intrinsic pontine glioma, anaplastic astrocytoma, recurrent ependymoma, and diffuse hemispheric glioma. Overall survival ranged from 4.1 to 47.7 months, and progression-free survival ranged from 1.7 to 47.7 months. Treatment was generally well tolerated; the most common adverse events were fever, headache, and nausea, while serious adverse events were infrequent and primarily related to disease progression. Many patients also received standard therapies such as surgery, radiotherapy, or chemotherapy.

CONCLUSION:

OVT appears safe and feasible in pediatric brain tumors, with signals of clinical benefit in selected patients. Larger, controlled trials are needed to clarify its survival impact and define optimal therapeutic strategies.

2025-02-01·Biochemical genetics

The Combinatorial Effect of Ad-IL-24 and Ad-HSV-tk/GCV on Tumor Size, Autophagy, and UPR Mechanisms in Multiple Myeloma Mouse Model

Article

作者: Hosseini, Seyed Younes ; Irani, Shiva ; Abdoli, Asghar ; Poorghobadi, Shima ; Baesi, Kazem ; Sadat, Seyed Mehdi

Multiple myeloma is a type of malignant neoplasia whose treatment has changed over the past decade. This study aimed to investigate the effects of combination of Adenovector-carrying interleukin-24 and herpes simplex virus 1 thymidine kinase/ganciclovir on tumor growth, autophagy, and unfolded protein response mechanisms in mouse model of multiple myeloma. Six groups of mice, including Ad-HSV-tk/GCV, Ad-IL-24, Ad-HSV-tk/IL-24, Ad-GFP, and positive and negative controls, were investigated, and each group was injected every 72 h. The tumor size was measured several times. The expression of LC3B evaluated through western blotting and ASK-1, CHOP, Caspase-3, and ATF-6 genes in the UPR and apoptosis pathways were also analyzed by the quantitative polymerase chain reaction (qPCR) method. The present results showed that the injection of Ad-HSV-tk/GCV, Ad-HSV-tk/IL-24, and metformin reduced the tumor size. The expression of LC3B was significantly higher in the treatment groups and positive control groups compared to the negative control group. The expression of CHOP, caspase-3, and ATF-6 genes was significantly higher in the Ad-IL-24 group compared to the other treatment groups. Besides, the ASK-1 expression was significantly lower in the Ad-IL-24 group as compared to the other groups. Overall, the results indicated that the presence of the HSV-tk gene in the adenovectors reduced the size of tumors and induced autophagy by triggering the expression of LC3B protein. The presence of the IL-24 might affect tumor growth but not as much the therapeutic effect of HSV-tk. Furthermore, the results indicated that co-administration of IL-24 and HSV-tk had no synergistic effect on tumor size control.

197

项与 Aglatimagene besadenovec 相关的新闻（医药）

2026-06-25

·BioSpace

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

Appointment supports planned Biologics License Application (BLA) submission in the fourth quarter of 2026 and potential 2027 launch of aglatimagene besadenovec in localized prostate cancer NEEDHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Mark Sims as the Company’s Chief Commercial Officer, effective July 6, 2026. Mr. Sims will lead Candel’s commercial strategy and launch readiness for aglatimagene besadenovec (aglatimagene or CAN-2409) in intermediate- to high-risk localized prostate cancer. “The appointment of Mark Sims represents another important step in Candel's evolution toward becoming a potential commercial-stage oncology company. With positive phase 3 clinical trial data, the FDA’s Regenerative Medicine Advanced Therapy designation, a planned BLA submission for aglatimagene in the fourth quarter of 2026, and preparation for a potential commercial launch already underway, we are building the capabilities required to bring aglatimagene, if approved, to patients as efficiently as possible,” said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. “We believe that intermediate- to high-risk localized prostate cancer represents a large and well-defined market opportunity, with approximately 65,000 patients diagnosed annually in the United States who are candidates for radiotherapy-based treatment approaches with curative intent. Mr. Sims has led and scaled some of oncology’s most significant franchises, and we believe his deep experience bringing innovative therapies to market will be instrumental to making aglatimagene, if approved, available to patients.” Aglatimagene is an off-the-shelf, replication-defective adenovirus designed to induce immunogenic cell death and activate a systemic anti-tumor immune response. The Company has adopted a partnership-driven commercial model, working with EVERSANA on commercialization and IDEA Pharma on strategic positioning, designed to provide immediate access to leading commercial capabilities while maintaining the financial flexibility that has characterized Candel’s approach to development. Commercial preparations are underway across market access, medical affairs, manufacturing, physician engagement, and launch planning activities. Mr. Sims will work closely with these partners as Candel prepares for a potential commercial launch of aglatimagene following its planned BLA submission in the fourth quarter of 2026. “Aglatimagene has the potential to establish a new treatment paradigm in localized prostate cancer by combining a differentiated mechanism of action with a practical treatment approach that can be readily integrated into existing radiotherapy workflows. The strength of the phase 3 data, together with Candel’s thoughtful and capital-efficient commercialization strategy, creates a compelling opportunity to deliver meaningful value for patients, physicians and shareholders,” said Mark Sims, who will join Candel as Chief Commercial Officer on July 6, 2026. Mr. Sims is a seasoned oncology commercial leader with more than 25 years of experience building and advancing Global and US cancer franchises. Most recently, he served as Vice President and Global Franchise Head for EGFRm Lung Cancer at AstraZeneca, where he led global commercial strategy for one of the company’s largest business franchises. During his eight-year tenure at AstraZeneca, he also served as Global Commercial Head - Lung Cancer, Head of Oncology Business Unit - Canada, and US Business Franchise Head – DDR/Women’s Cancer. Prior to AstraZeneca, Mr. Sims spent a decade at Novartis in various senior oncology leadership roles, including Vice President and Global Disease Lead for Breast Cancer and Business Franchise Head for Hematology in Canada. Earlier in his career, he held commercial positions at Idenix Pharmaceuticals and Merck & Co. Inc. Mr. Sims earned an MBA from the Thunderbird School of Global Management, Arizona State University and a Bachelor of Commerce from McMaster University. About aglatimagene besadenovec (CAN-2409) Aglatimagene, Candel’s most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s tumor. After intratumoral administration, HSV-tk enzyme activity results in conversion of prodrug (valacyclovir) into deoxyribonucleic acid (DNA)-incorporating nucleotide analogs, leading to immunogenic cell death in cells exhibiting DNA damage and proliferating cells, with subsequent release of a variety of tumor (neo)antigens in the tumor microenvironment. At the same time, the adenoviral serotype 5 capsid proteins promote inflammation through the induction of expression of pro-inflammatory cytokines, chemokines, and adhesion molecules. Together, this regimen is designed to induce an individualized and specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity, based on in situ immunization against a variety of tumor antigens. Aglatimagene has the potential to treat a broad range of solid tumors. Encouraging monotherapy activity as well as combination activity with standard of care radiotherapy, surgery, chemotherapy, and immune checkpoint inhibitors have previously been shown in several preclinical and clinical settings. More than 1,000 patients have been dosed with aglatimagene in clinical trials with a favorable tolerability pro date, supporting the potential for use with standard of care, when indicated. Aglatimagene is currently not approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for any use. About Candel Therapeutics Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the FDA. The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC. Linoserpaturev (CAN-3110) is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in Nature and Science Translational Medicine and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. For more information about Candel, visit: . Forward-Looking Statements This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the submission of the BLA for aglatimagene in intermediate- to high-risk localized prostate cancer; expectations regarding early biological readouts as predictor of clinical response; expectations regarding the therapeutic benefit of the Company’s platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult-to-treat, solid tumors; expectations regarding the potential benefits conferred by regulatory designations; and expectations regarding the potential benefits conferred by the publication of the Company’s findings in The Lancet Oncology . The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; the impact of the Company’s existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Investor Contact Theodore Jenkins Vice President, Investor Relations, and Business Development Candel Therapeutics, Inc. tjenkins@candeltx.com Media Contact Ben Shannon ICR Healthcare CandelPR@icrhealthcare.com

快速通道临床2期临床3期高管变更免疫疗法

2026-06-17

·凤凰涅槃之路

永远在黎明前：溶瘤病毒七十年沉浮与下一次机会

肿瘤学史上，从未有哪个疗法像溶瘤病毒一样，始终处于"即将突破"的状态长达数十年。它的叙事足够动人——用病毒感染并摧毁癌细胞，同时唤醒免疫系统对抗肿瘤，犹如在癌细胞内部埋下了一枚精确引爆的炸弹。这个概念在上世纪50年代就已萌芽，历经七十年的起伏，全球至今只有寥寥几个上市产品，其中大多数销量惨淡，市场定价昂贵却使用率极低。然而，2025年以来，这个赛道正在发生一些真实的变化：两篇来自中国的顶刊论文（Cell和Nature）相继发表，标志着中国科学家在该领域实现了从跟跑到并跑的转变；全球最有希望的下一代候选药物正在膀胱癌适应症上积累强劲数据；而国内的亦诺微医药已向港交所递交IPO申请，试图成为"溶瘤病毒第一股"。一、什么是溶瘤病毒：一个有三重作用机制的平台溶瘤病毒（Oncolytic Virus，OV）是指能够选择性感染肿瘤细胞并在其内部复制、最终导致肿瘤细胞裂解死亡的一类病毒，来源可以是天然存在的嗜肿瘤病毒，也可以是经过基因工程改造后获得肿瘤选择性的工程病毒。与传统化疗、靶向药和免疫检查点抑制剂相比，溶瘤病毒的理论优势在于三重叠加机制，而这三重机制正是它令人着迷的核心所在。第一重：直接溶瘤（Oncolysis）。病毒进入肿瘤细胞后大量复制，最终撑破细胞膜，导致细胞裂解死亡。这一过程与化疗的非特异性杀伤不同，理论上具有肿瘤选择性，肿瘤细胞普遍存在干扰素信号通路缺陷，无法像正常细胞一样阻止病毒复制。第二重：免疫原性死亡（Immunogenic Cell Death）。肿瘤细胞裂解时，释放出大量肿瘤相关抗原、危险信号分子和细胞因子，这些分子相当于一枚"信号弹"，能够激活树突细胞，进而启动适应性免疫反应，让T细胞识别并攻击其他未被病毒感染的肿瘤细胞。第三重：系统性肿瘤免疫。局部注射的溶瘤病毒不仅能够杀伤被感染的肿瘤细胞，还可能通过激活全身免疫反应，对远处未注射病灶产生间接杀伤作用。这种现象通常被称为“远隔效应（abscopal effect）”。然而，这一效应在个案报道和早期临床研究中虽偶有出现，却始终难以在大规模临床试验中稳定重现，因此也是溶瘤病毒领域最具吸引力、同时最具争议的价值主张之一。二、70年历史：一部充满误判的进化史溶瘤病毒并非新概念。早在1904年，医学文献中就已出现病毒感染后肿瘤自发消退的临床观察记录，彼时研究者尚不理解其机制，仅将其视为偶发现象。1950至1960年代，部分研究者开始有意识地将野生型病毒直接注射入肿瘤，尝试将这一现象转化为疗法。然而由于缺乏基因工程手段，野生型病毒的肿瘤选择性极差，既不能保证疗效，也无法控制对正常组织的毒性，该方向随后进入漫长的沉寂期。 1990年代，基因工程技术的成熟使研究者第一次能够对病毒基因组进行精确改造，溶瘤病毒研究迎来真正意义上的第一个科学高峰。研究者可以系统性地删除病毒的致病基因以提高安全性，同时保留或增强其在肿瘤细胞中复制的能力，由此奠定了现代溶瘤病毒药物的技术基础。 2005年，中国成为全球第一个批准溶瘤病毒上市的国家。上海医药旗下子公司三维生物研发的安柯瑞（重组人5型腺病毒注射液，H101）获NMPA批准，适应症为联合化疗治疗晚期鼻咽癌，并于2006年正式上市销售。然而这一历史性的"全球第一"并未引发预期中的市场反应。安柯瑞的临床数据基于国内试验，在国际评价标准下存在广泛争议，缺乏符合全球监管规范的大规模随机对照数据，因此始终未能进入国际主流市场。在国内，产品定价昂贵，使用场景受限，销量长期边缘化。上海医药后来在公开场合坦承安柯瑞"不是集团的重点产品"——这句话，某种程度上也是整个早期溶瘤病毒时代的注脚。 2015年是溶瘤病毒历史上真正具有分水岭意义的年份。安进（Amgen）的T-VEC（talimogene laherparepvec，商品名Imlygic）获FDA批准，成为西方世界第一个上市的溶瘤病毒药物，适应症为不可切除的晚期黑色素瘤。T-VEC基于单纯疱疹病毒1型（HSV-1）改造，删除了两处ICP34.5神经毒性基因以实现减毒，同时插入粒细胞-巨噬细胞集落刺激因子（GM-CSF）编码序列以激活抗肿瘤免疫。三期注册性临床OPTIM试验数据显示，T-VEC在不可切除的III/IV期黑色素瘤患者中的持续缓解率为16.3%，显著优于GM-CSF单药的2.1%。这是溶瘤病毒领域第一次在严格设计的三期随机对照试验中证明了有效性，意义不可低估。然而，T-VEC上市后的真实商业表现令人失望。一个疗程费用高达6.5万至8万美元，但给药方式仅限瘤内注射，对广泛转移的病灶完全无能为力，这极大地制约了其临床适用人群。更具决定性的打击来自后续的联合研究：T-VEC与PD-1抑制剂pembrolizumab联用的大型三期试验MASTERKEY-265宣告失败，两药联合在无进展生存期和总生存期上均未能显示出优于pembrolizumab单药的统计学优势。这一结果彻底暴露了第一代溶瘤病毒的核心局限——局部注射的病毒无法在系统层面产生足以叠加于成熟免疫检查点抑制剂之上的增量获益。市场的热情随之骤降。 2021年，日本第一三共的Delytact（G47Δ）获日本厚生劳动省条件性批准，适应症为恶性胶质母细胞瘤。Delytact同样基于HSV-1，通过三处关键基因的缺失实现对脑肿瘤细胞的高选择性，是溶瘤病毒在技术层面最精密的改造成果之一。但胶质母细胞瘤的患者群体极度稀少，治疗可及性受限，Delytact在商业上亦难有大作为。至此，溶瘤病毒在2025年之前的全部上市成果清晰呈现：三个获批产品，分属三个市场，代表三种不同形式的"有限成功"。安柯瑞数据不被国际认可，T-VEC联合策略折戟三期，Delytact患者基数极度稀少。概念振奋人心，获批产品屈指可数，已上市产品商业表现普遍惨淡，多个被寄予厚望的大型三期临床试验以失败告终。这不是一个领域的失败，而是一系列结构性困境在历史中的持续显现。为什么会这样？答案需要深入技术层面寻找。三、为什么总在失败：四道结构性壁垒理解溶瘤病毒的困境，必须直视其技术层面的四道核心壁垒，而不是停留在"机制很好、数据令人失望"这样的表面描述。这四道壁垒并非相互独立，而是层层叠加：药进不去，进去了免疫系统先清除病毒，清除不干净肿瘤微环境也能压制免疫激活，而整个过程的制造成本又封死了大规模应用的可能。壁垒一：递送困境：进不去、打不到。溶瘤病毒最现实的给药方式是瘤内注射，即直接将病毒注射进可触及或影像引导下可访问的肿瘤病灶。这一方式对局部病灶有一定效果，但对远处转移灶完全无能为力，严重限制了适用人群。系统性给药（静脉注射）是解决转移性疾病的逻辑选择，但面临三重障碍。其一，人体血液中存在大量预存中和抗体，许多患者对常见病毒骨架（如HSV、腺病毒）已有免疫记忆，注射进血流的病毒在抵达肿瘤之前就被迅速清除，半衰期极短。其二，病毒颗粒会被网状内皮系统（主要是肝脏和脾脏）大量截留吞噬，难以在血液中维持有效浓度。其三，实体瘤内部的高间质压和致密细胞外基质构成物理屏障——肿瘤内部流体静水压往往高于血管压，即使病毒抵达肿瘤周边，也极难均匀渗透进肿瘤实质深部。当前研究中探索纳米颗粒包裹、间充质干细胞作为病毒载体等方案，本质上都是在试图突破这道物理瓶颈。壁垒二：免疫双刃剑：杀毒还是杀瘤？溶瘤病毒的设计初衷是激活抗肿瘤免疫，但免疫系统的响应并不区分"病毒"与"携带病毒的肿瘤细胞"。机体免疫应答启动后，针对病毒衣壳蛋白的中和抗体迅速产生，在清除病毒的同时也限制了后续给药的疗效。多次给药后，这种"抗载体免疫"往往反而成为治疗的主要障碍。这是一个进化层面的内在矛盾：我们利用病毒的免疫原性来激活抗肿瘤反应，但人体的进化本能是优先清除病毒。免疫功能低下的患者（如长期化疗后）这一问题相对较轻，但这类患者整体状态差，从免疫激活机制中获益也更加有限。两头都被堵死，难以通过简单的工程改造绕开。壁垒三：肿瘤微环境的免疫抑制性。溶瘤病毒在"冷肿瘤"中发挥作用的前提，是能够把免疫抑制性微环境"变热"。但现实是，冷肿瘤微环境中的调节性T细胞（Treg）、髓系来源的抑制性细胞（MDSC）以及TGF-β、IL-10等大量免疫抑制因子，共同构成了一个极为顽固的抑制性生态。溶瘤病毒注射后，肿瘤细胞裂解确实释放了抗原，但这些抗原随即被微环境中的免疫抑制信号覆盖，无法激发足够强度且持久的T细胞杀伤力，免疫激活呈短暂性、局限性，难以形成系统性的抗肿瘤响应。这也是为什么溶瘤病毒单药疗效普遍有限，而联合免疫检查点抑制剂（ICI）虽然在机制上看似合理，却始终难以在大型临床试验中稳定证明额外获益。T-VEC联合pembrolizumab三期试验的失败，正说明仅靠增加局部免疫激活，并不足以突破实体瘤微环境的深层免疫抑制。壁垒四：制造工艺的复杂性与成本。溶瘤病毒属于生物制品中制造难度最高的类别之一。与单克隆抗体的标准化生产相比，病毒制品的扩增过程容易发生变异，提纯需要在保持活性的同时去除全部细胞碎片和杂质，储存往往依赖超低温冷链——每一个环节都是成本黑洞。生产成本极高直接决定了终端定价高企，定价高企压缩了支付方（无论医保还是商业保险）的推广意愿，而制造工艺的刚性也限制了临床试验中给药方案的灵活性。这四道壁垒共同构成了一个自我强化的困局：高成本让商业化难以为继，商业化困难抑制了研发投入，研发投入不足又使技术突破迟迟难以落地。溶瘤病毒长期处于"永远在黎明前"的状态，根源正在于此。四、全球已上市产品与主要管线：真实的市场图谱全球已获批上市产品全球已获批上市的溶瘤病毒产品只有三个：2005年中国NMPA批准的安柯瑞（腺病毒，上海三维生物/上海医药，晚期鼻咽癌）、2015年FDA批准的Imlygic即T-VEC（HSV-1，Amgen，晚期黑色素瘤）、以及2021年日本条件性批准的Delytact即G47Δ（HSV-1，第一三共，胶质母细胞瘤）。三个产品，三个市场，三种意义上的"有限成功"。安柯瑞数据不被国际认可；T-VEC大型联合试验失败后商业逻辑动摇；Delytact的适应症人群极度稀少。这是溶瘤病毒在2025年之前全部的商业化成果。三个产品，三个市场，三种意义上的"有限成功"。安柯瑞数据不被国际认可；T-VEC大型联合试验失败后商业逻辑动摇；Delytact的适应症人群极度稀少。这是溶瘤病毒在2025年之前全部的商业化成果。全球最重要的在研管线以下管线代表当前赛道的临床前沿，按进展成熟度排列。 CG Oncology——CG0070（cretostimogene grenadenorepvec）目前全球溶瘤病毒赛道最有临床说服力的在研产品，行业内公认的"最有可能率先获批"候选。CG0070基于腺病毒改造，针对膀胱癌，给药方式为膀胱内灌注，从根本上规避了静脉递送的所有障碍。三期注册性临床BOND-003数据持续稳健：在BCG无响应的高危非肌层浸润性膀胱癌（NMIBC）患者中，12个月完全缓解率75.2%，24个月完全缓解率41.8%，且12个月获得完全缓解的患者中90%在24个月仍维持缓解，安全性方面无三级及以上治疗相关不良事件。公司已于2025年第四季度启动滚动BLA递交，与FDA对齐后确认完整提交预计于2026年第四季度完成，账上现金约11亿美元，资金可覆盖至2029年。乐普医疗持有CG0070的中国合作权益。 CG0070的战略价值在于找到了溶瘤病毒与适应症的最优匹配：腔内给药完全绕开系统递送难题，BCG耐药NMIBC患者面临膀胱切除术或带病生存的两难困境，未满足需求极为明确。这是整个赛道"适应症选择决定成败"最有说服力的范本。 Replimune——RP1（vusolimogene oderparepvec） RP1基于HSV-1改造，携带GALV-GP R和GM-CSF，设计逻辑是最大化肿瘤杀伤和免疫激活。在黑色素瘤1/2期IGNYTE试验中，RP1联合nivolumab对PD-1治疗失败患者的ORR约33%，完全缓解率15%，3年生存率54.8%，数据令人印象深刻。然而RP1的监管历程是2025至2026年整个溶瘤病毒赛道最惨烈的教训。2025年7月收到第一次CRL后，公司重新递交申请，2026年4月10日再次收到第二次CRL，FDA认定数据"不足以得出实质性有效性结论"，理由仍指向IGNYTE试验设计缺乏对照和患者异质性。两次被拒后，Replimune CEO明确表示若无法获得加速批准，RP1的开发将不再可行，公司随即宣布大规模裁员和管线重组。IGNYTE-3三期试验仍在进行，但前景高度不确定。RP1案例的核心警示是：即便临床数据令人信服、已获突破性疗法认定，单臂试验设计加上异质性人群，仍可能在监管层面被彻底封死。 Genelux——Olvi-Vec（olvimulogene nanivacirepvec） Olvi-Vec基于改造后的牛痘病毒，是赛道内为数不多挑战腹腔内给药策略的候选产品。核心思路是利用腹腔给药使铂耐药卵巢癌肿瘤微环境重塑，重新恢复对铂类化疗的敏感性。三期注册性临床OnPrime/GOG-3076已完成入组，独立数据监察委员会2026年2月审查后建议继续推进，顶线数据预计2026年下半年公布。若成功，将是溶瘤病毒在妇科肿瘤的首次三期突破；若失败，则进一步验证实体瘤腔内给药策略在卵巢癌中的困难性。公司现金约2600万美元，资金仅能覆盖至2027年初，存在融资压力。 Oncolytics Biotech——Pelareorep 天然呼肠孤病毒，可静脉注射，预存中和抗体水平在人群中相对较低，是当前赛道内最成熟的静脉给药产品。主要在乳腺癌和胰腺癌适应症推进联合化疗及免疫检查点抑制剂的联合方案，多项临床试验进行中。2026年6月获得新制造工艺专利，显示公司持续在解决规模化生产壁垒。单药疗效数据有限，整体推进节奏偏慢，但静脉给药可行性是其相对于HSV和腺病毒类产品的差异化优势。国内阿诺医药已引进其中国权益并推进注册性试验。 Candel Therapeutics——CAN-2409 基于腺病毒的产品，专注于前列腺癌和胰腺癌，瘤内或超声引导下局部注射给药。2026年5月AUA年会上公布前列腺癌三期延伸随访数据，显示持续的生存获益信号。公司规模较小，资金有限，但前列腺癌局部病灶的适应症选择逻辑清晰，是小公司在赛道内找准位置的代表案例。五、2025年的两个中国突破：Cell和Nature的双杀 2025年初，两项来自中国的研究几乎同步发表于Cell和Nature，打破了溶瘤病毒领域长期以来以欧美为技术中心的格局，也为整个赛道注入了新的想象空间。广西医科大学赵永祥团队（Cell，2025年1月）赵永祥团队开发了工程化溶瘤新城疫病毒 NDV-GT，通过插入猪 α1,3GT 基因，使肿瘤细胞表面表达 Galα1-3Gal 抗原，诱导人体预存的超急性排斥反应（HAR），将肿瘤“伪装”为异种移植物，从而招募大量免疫细胞攻击肿瘤。研究采用介入方式将病毒直接递送至肿瘤血供，避免静脉给药面临的中和抗体限制。在20例完成治疗的复发/难治性转移性实体瘤患者中，疾病控制率（DCR）达到90%，包括1例完全缓解（CR）、6例部分缓解（PR）和11例疾病稳定（SD）。该研究首次将异种移植免疫学中的HAR机制引入溶瘤病毒治疗，为激活抗肿瘤免疫提供了全新思路。不过，目前数据仅来自20例Ⅰ期临床患者，仍需更大规模研究验证。浙江大学梁廷波团队 & 复诺健生物——VG161（Nature，2025年3月） VG161是目前全球临床阶段装载免疫调控基因最多的溶瘤病毒之一。该产品基于HSV-1构建，同时表达IL-12、IL-15、IL-15Rα及PD-L1阻断肽四种免疫调控因子，旨在通过多重机制重塑肿瘤免疫微环境。Nature发表的研究报道了VG161在晚期肝细胞癌（HCC）多中心Ⅰ期临床中的安全性和初步疗效。此前，VG161已获得FDA快速通道资格（2023年）和NMPA突破性治疗药物认定（2024年）。VG161代表了中国企业在“武装型溶瘤病毒”领域的领先水平。Nature发表叠加监管突破，使其成为目前中国溶瘤病毒赛道最具代表性的临床资产之一。选择肝癌作为核心适应症也具有鲜明的中国特色——中国约占全球55%的肝癌病例，是全球疾病负担最重的市场。六、中国的整体竞争格局中国溶瘤病毒产业的特点是起步偏早（安柯瑞2005年即获批）、基础参差不齐、近年头部企业快速向国际标准靠拢。以下是值得重点追踪的中国公司图谱。亦诺微医药（ImmVira）深圳公司，目前中国溶瘤病毒领域管线最广、临床推进最快的纯溶瘤病毒公司。核心产品MVR-T3011基于HSV-1，同时编码抗PD-1抗体和IL-12，实现"3合1"武装设计（溶瘤 + 免疫检查点抑制 + 细胞因子）。目前MVR-T3011在中国和美国同时开展II期临床，适应症涵盖头颈部鳞状细胞癌、膀胱癌等实体瘤，并与罗氏开展联合MEK抑制剂cobimetinib的研究。亦诺微于2026年1月向港交所递交IPO申请，花旗和中金担任联席保荐人，拟成为港股"溶瘤病毒第一股"，C+轮投后估值约4.85亿美元。除溶瘤病毒产品线外，亦诺微还布局了工程化外泌体递送平台，体现出向更广义"生物载体递送"转型的战略意图。复诺健生物（Virogin Biotech）核心资产VG161是目前全球临床阶段携带免疫调控基因数量最多的溶瘤病毒，已在Nature发表1期临床数据，并获NMPA突破性治疗药物认定与FDA快速通道认定。公司由美国溶瘤病毒领域资深科学家创立，具备在同一病毒骨架上灵活更换外源基因的模块化平台优势。VG161大中华区商业化独家权益已授权给中生复诺健（国药集团参与的合资主体），复星医药通过旗下基金参股复诺健，持有财务投资人地位，不直接掌控商业化进程，BD尽调时需厘清这一权益结构。在生态延伸上，复诺健已与康方生物合作推进新一代管线VG201联合依沃西治疗结直肠癌肝转移；VG161 IV（静脉注射版本）亦在探索更广适应症，是国内为数不多在系统给药方向有真实布局的产品。滨会生物武汉公司，核心产品BS001（OH2）基于HSV-2骨架，已获FDA孤儿药认定（黑色素瘤），处于临床探索阶段，适应症涵盖黑色素瘤、肝癌等。体量相对较小，专注度较高。荣瑞医药上海公司，核心产品OVV-01是基于水疱性口炎病毒（VSV）改造的全球首创溶瘤病毒，携带NY-ESO-1肿瘤相关抗原，设计逻辑为溶瘤同时释放强免疫原性抗原激活肿瘤特异性免疫应答。2024年9月同时获FDA I期和II期IND批件，2025年3月获FDA快速通道认定，是国内骨架类型最具差异化的溶瘤病毒产品之一。公司规模偏小，整体仍处于临床早期，但VSV骨架在人群中预存抗体水平极低，在递送壁垒上有天然优势。恒瑞医药曾于2016年从日本Oncolys公司引进溶瘤病毒产品OBP-301，但已于2020年终止合作。目前恒瑞在溶瘤病毒领域无清晰可见的自研平台布局，反映出大型药企在该赛道试错后趋于观望的态度。复星医药、乐普医疗复星医药通过旗下基金参股复诺健生物，持有财务投资人地位，间接参与VG161生态。乐普医疗则通过与CG Oncology的战略合作获得CG0070的中国权益，是国内接触到目前最有临床说服力在研产品的公司，将受益于CG0070若在美国获批后对中国监管申报的杠杆效应。总体而言，中国溶瘤病毒产业仍处于以临床早期为主的阶段，头部企业（亦诺微、复诺健）在国际同行中已具备竞争力，但距离商业化获批仍需数年。国内没有任何一个溶瘤病毒产品在近期（2025-2027年）有明确的获批路径，这是必须正视的事实七、市场规模：现实与预测之间的巨大落差溶瘤病毒的市场数据是这个赛道中最混乱的部分之一。来自不同机构的预测数字从数千万美元到数十亿美元不等，差异高达数十倍，折射出该领域高度不确定性的本质。当前可信数字是：2024年全球溶瘤病毒疗法销售额约为1000万至8000万美元（不同数据源差异较大），考虑到仅有T-VEC在美欧有真实商业化历史且销量有限，这个区间的下端可能更接近现实。市场预测方面，多数机构给出的2030-2031年全球市场规模在15亿至25亿美元区间，CAGR普遍在20%以上。这些预测的前提假设是：CG0070在膀胱癌获批，新一代武装化OV联合ICI疗法在多个适应症陆续推进，静脉给药技术取得突破。若以上假设不能兑现，实际市场规模可能显著低于预期。中国市场的情况更难评估。安柯瑞虽然长期在市，但医院使用极为有限。未来的中国市场增长将很大程度上依赖VG161和亦诺微产品线能否实现商业化获批，以及进入医保体系的可能性。八、技术演进的三条路径：下一代OV的突破方向如果把已经失败或表现平平的第一代溶瘤病毒（T-VEC类、安柯瑞类）视为1.0时代，当前的技术演进正沿着三条路径向2.0时代推进。路径一：武装化：装载更多弹药。这是当前最主流的工程化方向。在病毒基因组中插入多个治疗性基因，使病毒复制的同时在肿瘤微环境局部产生大量活性蛋白。代表产品是VG161（IL-12 + IL-15 + IL-15Rα + PD-L1阻断肽）和MVR-T3011（抗PD-1 + IL-12）。与其依靠全身性给予细胞因子或免疫检查点抗体（会产生系统毒性），不如利用病毒作为"局部递送载体"，在肿瘤内部原位分泌这些活性物质，实现更高的局部浓度和更低的系统毒性。这在早期临床数据中已显示出吸引力，但能否转化为三期试验的生存获益仍需验证。路径二：递送突破：解决进不去的问题。这是溶瘤病毒领域最根本的技术难题，也是创新最活跃的方向。当前的探索包括：利用干细胞作为"细胞载体"携带病毒穿越血-脑屏障（Calidi Biotherapeutics的NeuroNova平台）；通过物理或化学方法屏蔽病毒表面抗原（"病毒隐身"技术），延长其在血液中的循环时间；开发新型病毒骨架（如使用人群中预存抗体较低的新城疫病毒、牛痘病毒等），减少免疫清除；以及广西医科大学的介入给药方法，通过导管直接将病毒递送至肿瘤供血动脉附近。路径三：联合治疗：与其他疗法协同。这是现阶段临床试验数量最多的方向。主要组合包括：OV + ICI（最常见，但大型试验迄今未证明优于ICI单药）；OV + CAR-T（理论上OV可将免疫抑制性实体瘤改造成对CAR-T更友好的微环境，Transgene与PersonGen的合作为代表）；OV + 靶向药（如MEK抑制剂，通过阻断肿瘤细胞的干扰素响应通路增强OV复制）；OV + 化疗。联合治疗的逻辑最容易被市场接受，但在临床设计上最复杂，失败风险也最高。T-VEC + pembrolizumab失败已是前车之鉴。九、监管逻辑：审批标准正在提高溶瘤病毒的监管历史提供了重要启示。FDA对这类产品的审批标准，随着该领域临床积累的增加，正在变得更加严格而非更加宽松。 Replimune RP1的BLA被拒（2025年7月），FDA明确指出单臂1/2期试验不足以构成批准依据，且认为IGNYTE试验的患者异质性过高。这意味着未来溶瘤病毒申请FDA批准，需要设计严格的随机对照试验，而非依靠单臂高ORR数据走加速审批路径。这对整个行业的临床开发策略是一个重要信号。相比之下，CG0070获得突破性治疗认定后的BLA路径更加清晰，原因在于膀胱内灌注的给药方式、单药对照（无ICI参与）的试验设计，以及BCG无效NMIBC这一清晰的患者人群和疗效终点。这再次印证了适应症选择的战略重要性。中国NMPA对VG161授予突破性治疗认定，表明国内监管对于有真实数据支撑的溶瘤病毒产品持开放态度，但同样需要随机对照数据方可注册上市。十、风险矩阵：这个赛道最不能忽视的七个风险任何对溶瘤病毒的分析，如果回避风险，都是不诚实的。风险一：从早期数据到三期成功之间存在巨大鸿沟。溶瘤病毒从1/2期积极数据到三期成功的转化率，是所有肿瘤免疫疗法中最低的之一。根本原因在于单药疗效受递送问题的根本性制约，无论设计多精巧，联合疗法是必然出路，但随即引入了试验设计复杂性和对照组选择问题。T-VEC联合pembrolizumab的三期失败，以及RP1在2025年7月和2026年4月连续两次收到FDA的CRL、公司随即宣布裁员重组，都是这一风险的真实注脚。即使有突破性疗法认定、即使早期数据令人印象深刻，三期失败仍是大概率事件而非小概率风险。风险二：适应症选择决定成败。 CG0070在膀胱癌的成功逻辑与T-VEC在转移性黑色素瘤中的局限，本质上是适应症选择的高下之分。局部可给药、免疫微环境相对友好的适应症（膀胱癌、头颈癌局部病灶）才是OV的舒适区；试图用OV解决弥漫性转移癌的公司，其临床路径风险极高。这一判断对于评估任何早期管线的投资价值都至关重要。风险三：开发成本与周期被系统性低估。监管端，FDA已明确传达信号：需要随机对照试验、更大样本量、同质化患者人群，III期开发成本将显著高于早期估算。制造端，病毒GMP生产工艺复杂、成本高、放大困难，许多公司在管线推进到III期后才发现制造瓶颈，导致进度严重滞后。两者叠加，意味着从II期阳性数据到商业化上市所需的资金和时间，往往是创业公司最初预计的两到三倍。风险四：竞争格局的替代性风险。溶瘤病毒并非肿瘤免疫治疗的唯一创新路径。膀胱癌领域，TAR-200等新型局部递送系统、各类PD-L1抑制剂和ADC正在同步推进；黑色素瘤领域的ICI格局已高度成熟；更广泛的肿瘤学领域，ADC、双抗、细胞治疗持续涌现。即使CG0070获批，也面临市场份额争夺；溶瘤病毒在大多数适应症中很难成为一线标准治疗，更现实的定位是二线或联合方案中的组合选项。风险五：中国市场的时间风险。国内目前没有任何一款溶瘤病毒产品在近期（2025-2027年）有明确的获批路径，中国市场的商业化时间表与实验室的乐观预期之间存在相当大的落差。对于多数中国早期公司而言，未来几年更现实的路径可能并非独立完成全球商业化，而是在临床概念验证后通过License-out或国际合作实现价值兑现。投资于早期中国公司，需要对更长的回报周期有清醒预期。十一、凤凰观察： 1.先看给药方式，再看机制设计。一个溶瘤病毒产品的临床成功概率，在很大程度上由给药方式决定。能够规避中和抗体和系统递送问题的局部给药方案（腔内灌注、局部介入、直接瘤内注射），天然具有更高的临床可行性。静脉给药方案无论机制设计多精妙，在相同阶段的项目中风险溢价应当更高。 2.适应症的"技术-临床-市场"三角匹配。最值得关注的适应症是：现有标准治疗存在明确瓶颈（如BCG耐药的NMIBC）、肿瘤位置允许局部给药、免疫微环境相对可逆。满足以上三条的适应症，溶瘤病毒的价值主张最清晰。 3.差异化的武装化设计才有壁垒。仅携带单一基因（如GM-CSF）的第一代溶瘤病毒已经没有投资价值，而搭载多个精心选择的免疫调控基因的武装化OV，在机制设计上具有更强的差异化壁垒。但需要警惕的是，基因组合的选择需要有扎实的临床前免疫学依据，而非单纯的"多多益善"。 4.联合ICI是必要但不充分条件。与PD-1/PD-L1抑制剂联用已经成为溶瘤病毒的几乎标配，但这一组合在三期临床中的历史战绩并不乐观。BD谈判中，溶瘤病毒产品与ICI的联合方案本身不能构成核心价值点，必须辅以明确的患者分层策略和疗效预测生物标志物（predictive biomarker），才能在谈判中支撑合理估值。 5.关注CG0070的示范效应。如果CG0070在2026至2027年获得FDA批准，将是整个溶瘤病毒赛道一次历史性的估值重估事件，可能带动全球范围内（包括国内）相关公司的估值大幅上行。亦诺微、复诺健、乐普医疗（通过CG0070中国权益）都将直接受益于这一事件。这是该赛道目前最重要的催化剂，值得设立观察节点。溶瘤病毒是当前BD交易中定价最难的资产类别之一。一方面，机制叙事极具吸引力，容易出现早期数据被高估的情况；另一方面，三期转化的历史成功率偏低，里程碑结构设计必须覆盖足够的风险缓冲。可以重点关注以下条件的资产：拥有已入组且数据成熟的II期注册性试验、适应症具有局部给药可行性、武装化设计有清晰的机制-疗效假说、管理团队有OV产品开发全周期经验。尽量避免单纯基于1期安全性数据（RP1的教训已然如此）定高估值做早期BD。结语溶瘤病毒或许是肿瘤学史上"被预言最多次、兑现最少次"的疗法。七十年起伏告诉我们，这个赛道的核心矛盾从未真正消失：病毒进不去、待不住、免疫系统帮倒忙，这三个问题的解决程度，决定了溶瘤病毒能走多远。但2025年正在发生的事情，比之前任何时期都更接近真实的临床突破：CG0070在膀胱癌积累了目前OV赛道中样本量最大、随访最长的完全缓解数据；两篇中国顶刊论文在递送机制上提供了真正的创新思路；亦诺微的IPO申请则意味着中国市场的资本生态已经准备好给这个赛道定价。这不是"溶瘤病毒要成功了"的乐观叙事，而是"溶瘤病毒正在经历真实的技术分化，部分适应症下的产品已经到了最接近临床获批的节点"的客观判断。对于投资者而言，现在既不是无脑押注的时机，也不是彻底观望的时机。分化正在发生，关键在于能否在正确的适应症上，找到真正理解这个赛道的团队和产品。永远在黎明前，或许这一次，天真的要亮了。本文不构成投资建议。所有临床数据均来源于公开发表的研究及企业公告，读者应独立核实关键数据。 Zhong L, Gan L, Wang B, et al. Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients. Cell. 2025;188:1119–1136.e23. https://doi.org/10.1016/j.cell.2024.12.010 Shen Y, Bai X, Zhang Q, et al. Oncolytic virus VG161 in refractory hepatocellular carcinoma. Nature. 2025;641:503–511. https://doi.org/10.1038/s41586-025-08717-5 BIO 2026（San Diego）期间作者将参会，欢迎创新药研发、BD、投资及产业合作交流。作者：刘玉娥（Lucia Liu），PhD, DBA 哈佛医学院博士后，公众号「凤凰涅槃之路」创始人。长期关注创新药研发、BD交易、技术转化与生物医药投资。往期推荐 ADC的进化：从重磅炸弹到技术平台 AI时代的人工酶革命：从定向进化到生成式设计，下一个平台型药物赛道在哪里？ RDC赛道全景解析：ADC之后，放射性药物正在重写肿瘤治疗 DAC赛道全景解析：当精准递送遇上蛋白降解 AOC赛道全景深度解析：ADC之后，下一个百亿美元治疗模态是谁？资本为何重新押注RNA？从RNA Editing到RNA Therapeutics的下一轮竞赛美国开始审查License Deal：中国创新药出海迎来最大变数？礼来豪掷19亿美元押注RNA外显子编辑：下一代基因治疗平台正在浮出水面一场2.15亿美元融资背后：CDK2和双特异ADC正在崛起 105亿美元大单背后：辉瑞为什么选择信达？诺华为何持续加码血脑屏障（BBB）递送？ ASCO 2026：依沃西单抗之后，中国创新药进入全球竞争深水区美国要‘封杀’中国Biotech？出海黄金时代正在变天专利悬崖下：未来3年，什么样的Biotech最容易被Big Pharma收购？礼来再出手！最高2.02亿美元拿下非病毒DNA递送平台Engage 中国创新药，告别“白菜价”时代再生元23亿美元押注Parabilis：ADC之后，谁能攻进“细胞内禁区”？复星6000万美元押注阿尔茨海默症口服药 152亿美元押注“中国速度”：BMS联手恒瑞，重构跨国研发新范式 4.78亿美元押注“细胞清除”：勃林格殷格翰联手Immunitas，抢占下一代自免疗法新战场星锐医药近4000万美元融资：肝外递送成为in vivo CAR-T新战场为什么一个还没上市的药，也能值10亿美元？ GSK十亿美元押注苏州时安生物：减重药大战，开始进入siRNA时代？罗氏又翻车：这个热门抗炎靶点为何接连失灵？

2026-06-07

·道道之道

【本周医刊】2026年第23周医学期刊更新

2026年第23周（2026.05.31-2026.06.06）重要医学期刊论著更新如下： 1.综合期刊 LANCET 题目：Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial 翻译：CD40 配体抑制剂聚乙二醇化达匹利珠单抗治疗系统性红斑狼疮的疗效与安全性（PHOENYCS GO 研究）：Ⅲ期随机、双盲、安慰剂对照试验题目：Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial 翻译：替尔泊肽用于美国肥胖人群减重后的体重维持（SURMOUNT-MAINTAIN研究）：多中心、双盲、随机、安慰剂对照试验题目：Coronary microvascular dysfunction and cardiovascular outcomes (Multicenter FLOW-CMD Registry): a prospective, multicentre cohort study in South Korea 翻译：冠状动脉微血管功能障碍与心血管预后（FLOW-CMD多中心注册研究）：韩国前瞻性多中心队列研究 NEW ENGLAND JOURNAL OF MEDICINE 题目：Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation 翻译：左心耳封堵术与抗凝治疗用于心房颤动的对比研究题目：High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure 翻译：高流量氧疗与常规氧疗治疗急性低氧性呼吸衰竭的对比题目：All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia 翻译：初诊急性髓系白血病的全口服方案治疗 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 题目：Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: The TNK-PLUS Randomized Clinical Trial 翻译：发病 4.5~24 小时的缺血性卒中患者血管内治疗前静脉应用替奈普酶：TNK-PLUS随机临床试验题目：Adjunctive Intra-Arterial Alteplase After Successful Thrombectomy for Acute Ischemic Stroke: The CHOICE-2 Randomized Clinical Trial 翻译：急性缺血性卒中血栓切除术成功后辅助动脉内输注阿替普酶：CHOICE-2随机临床试验题目：Changes in Nonprofit Hospitals’ Finances, Operations, and Quality of Care After Using Management Consultants 翻译：非营利性医院聘请管理顾问后的财务、运营及医疗质量变化 NATURE MEDICINE 题目：Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial 翻译：口服小分子 GLP-1 受体激动剂阿莱格列隆治疗超重/ 肥胖人群：Ⅱb期随机、双盲、安慰剂对照试验题目：A socially assistive robot to support mental wellbeing in LGBTQ+ young people at risk of self-harm: a randomized controlled trial 翻译：社交辅助机器人干预存在自伤风险的性少数青少年心理健康：随机对照试验题目：AAV gene therapy for homozygous familial hypercholesterolemia: a phase 1 trial 翻译：腺相关病毒基因疗法治疗纯合子家族性高胆固醇血症：Ⅰ期临床试验题目：Spinal cord stimulation for upper limb motor function in people with chronic post-stroke hemiparesis: a feasibility trial 翻译：脊髓电刺激改善脑卒中后慢性偏瘫患者上肢运动功能：可行性试验题目：Human microglial transitions at the Aβ–tau inflection point associate with divergent pathways to dementia and resilience 翻译：β 淀粉样蛋白与tau 蛋白病变拐点处的人小胶质细胞表型转换，与痴呆发病通路及疾病抵抗能力相关题目：Assessing quality of childbirth care provided by skilled health personnel in Exemplar countries 翻译：示范国家专业医护人员助产服务质量评估题目：15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrentClostridioides difficile infection: a randomized phase 1b trial 翻译：15 菌株活体生物制剂与同源供体粪便菌群移植治疗复发性艰难梭菌感染：Ⅰb期随机试验题目：Medically tailored meals receipt and healthcare utilization and costs in Massachusetts’ Medicaid demonstration 翻译：马萨诸塞州医疗补助试点项目中，医用定制餐食对医疗服务利用及费用的影响题目：Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial 翻译：肿瘤靶向干扰素 -α 基因疗法治疗胶质母细胞瘤：Ⅰ期临床试验题目：Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial 翻译：赛沃替尼治疗MET扩增型胃及胃食管结合部腺癌：Ⅱ 期临床试验题目：SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial 翻译：靶向 SEZ6 的抗体药物偶联物ABBV-706 治疗晚期小细胞肺癌及其他实体瘤：Ⅰ期临床试验题目：MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial 翻译：靶向 MAGE-A4/MAGE-A8 的TCR 型双特异性T 细胞衔接器治疗复发/ 难治性实体瘤：Ⅰ期临床试验 BMJ-BRITISH MEDICAL JOURNAL 题目：Global, regional, and national levels and trends in older child, adolescent, and youth (5-24 years) all cause mortality from 1990 to 2024: modelling study 翻译：1990—2024 年全球、区域及国家层面5~24 岁大龄儿童、青少年及青年全因死亡水平与变化趋势：模型分析研究题目：Global, regional, and national levels and trends in under 5, infant, and neonatal mortality during 1990-2024 with projections to 2030 翻译：1990—2024 年全球、区域及国家层面5 岁以下儿童、婴儿及新生儿死亡水平与趋势，并对2030 年数据进行预测题目：Estimates of global causes of death for children and adolescents aged 5-19 in 2000-24: secondary data analysis using bayesian multinomial logistic regression 翻译：2000—2024 年全球5~19 岁儿童及青少年死亡病因估算：基于贝叶斯多项逻辑回归的二次数据分析题目：Systematic estimates of global causes of neonatal and under 5 mortality in 2000-24: secondary data analysis using bayesian multinomial logistic regression 翻译：2000—2024 年全球新生儿及5 岁以下儿童死亡病因系统性估算：基于贝叶斯多项逻辑回归的二次数据分析 LANCET DIGITAL HEALTH（本周无更新） NPJ DIGITAL MEDICINE 题目：Human-AI co-design for clinical prediction models 翻译：人机协同设计临床预测模型题目：Fundus to fluorescein angiography video generation as a retinal generative foundation model 翻译：从眼底图像生成荧光血管造影视频：视网膜生成式基础模型研究题目：Measurement fidelity, not model complexity, governs individual cognitive trajectory prediction in Parkinson's disease 翻译：帕金森病个体认知轨迹预测：关键在于测量保真度，而非模型复杂度题目：Proteomic clocks combined with deep learning phenotypes track eye aging and diseases 翻译：联合蛋白质组时钟与深度学习表型，追踪眼部衰老与病变题目：Systematic review and meta-analysis of AI in lung cancer metastasis imaging for diagnosis and prognosis 翻译：人工智能用于肺癌转移影像诊断及预后评估的系统综述与荟萃分析题目：Learning like a radiologist: a medical vision-language model for radiological image analysis via curriculum learning 翻译：效仿放射科医师学习模式：基于课程学习的医学视觉语言模型用于影像分析题目：Enhancing foundation model transfer for prostate cancer detection with patch-level contrastive learning 翻译：结合斑块级对比学习优化基础模型迁移能力，提升前列腺癌检出效果题目：ChatGPT in the diagnosis and management of complex polyneuropathies: comparative analysis with neurologists using real-world cases 翻译：ChatGPT 在复杂性多发性周围神经病诊疗中的应用：结合真实病例与神经科医师的对比分析题目：Portable biomechanics laboratory enables clinically accessible movement analysis from a handheld smartphone 翻译：便携式生物力学实验室：依托智能手机实现临床可用的运动功能分析题目：EyeRAG: graph retrieval-augmented generation for safe and accurate clinical dialogue in ophthalmology 翻译：EyeRAG：基于图检索增强生成技术，构建安全精准的眼科临床对话系统题目：Artificial intelligence for the prediction of prognosis in colorectal cancer patients using routine blood indices 翻译：基于常规血液指标的人工智能模型预测结直肠癌患者预后题目：Age, emotional burden and deep brain stimulation electrode location shape Parkinson’s disease quality of life 翻译：年龄、情绪负担与脑深部电刺激电极位置对帕金森病患者生活质量的影响题目：Effects of digital versus face-to-face peer support on clinical skills: a three-arm randomized trial 翻译：线上同伴支持与线下面对面同伴支持对临床技能的影响：三臂随机对照试验题目：Fully automated system predicts osteoporotic vertebral fracture across institutions using lumbar MRI paraspinal muscle signatures 翻译：全自动系统利用腰椎 MRI 椎旁肌特征，跨机构预测骨质疏松性椎体骨折题目：Towards a clinically integrated artificial intelligence tool for triage of skin cancer 翻译：面向临床落地的人工智能皮肤癌分诊工具研发题目：Physics-informed deep learning enables reliable and scalable organoid quantification for drug screening via OCT 翻译：融合物理先验的深度学习技术，依托光学相干断层扫描实现类器官高通量精准量化，服务药物筛选题目：Interpretable graph deep learning framework for drug synergy prediction by integrating functional and clinical similarities 翻译：整合功能与临床相似性的可解释图深度学习框架，用于药物协同作用预测题目：A multimodal deep learning model predicting hyperprogressive disease for PD-1 blockade in advanced hepatocellular carcinoma 翻译：多模态深度学习模型预测晚期肝细胞癌患者PD-1 抑制剂治疗后的疾病超进展题目：Clinical outcomes and reporting quality of large language model interventions in practice: a systematic evidence map 翻译：大语言模型临床应用的疗效与报告质量：系统性证据图谱分析题目：A large-scale vision foundation model for musculoskeletal radiographs 翻译：面向肌肉骨骼放射影像的大规模视觉基础模型 2.肿瘤学 CA-A CANCER JOURNAL FOR CLINICIANS（本周无更新） ANNALS OF ONCOLOGY 题目：Future approaches to immune base biomarkers 翻译：免疫相关生物标志物的未来研究方向题目：Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer 翻译：基于多模态人工智能预测阿比特龙疗效：两项STAMPEDE Ⅲ 期非转移性极高危前列腺癌试验分析题目：Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer 翻译：SOFT 与TEXT 两项Ⅲ 期试验最终结果：绝经前激素受体阳性早期乳腺癌研究题目：Chemotherapy for patients with circulating tumour DNA positive, stage II colon cancer (CIRCULATE) – an AIO / ABCSG trial 翻译：循环肿瘤 DNA 阳性的Ⅱ 期结肠癌患者化疗研究（CIRCULATE）——德国肿瘤学工作组/ 奥地利乳腺癌与结直肠癌工作组联合试验题目：A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3 翻译：恩考芬尼联合西妥昔单抗、FOLFIRI 方案对比FOLFIRI± 贝伐珠单抗治疗BRAF V600E 突变结直肠癌的随机研究：BREAKWATER试验第3 队列 JOURNAL OF CLINICAL ONCOLOGY 题目：Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial 翻译：紫杉烷联合曲妥珠单抗、帕妥珠单抗 ± 卡铂用于HER2 阳性乳腺癌新辅助治疗：Ⅲ期随机非劣效性neoCARHP 试验题目：HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer 翻译：HER2CLIMB-05：图卡替尼对比安慰剂联合曲妥珠单抗、帕妥珠单抗作为HER2 阳性转移性乳腺癌一线维持治疗的Ⅲ 期研究题目：Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia 翻译：基于分子特征的综合诊疗体系助力慢性粒单核细胞白血病个体化治疗题目：Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study 翻译：埃万妥单抗单药治疗化疗耐药型 RAS/BRAF 野生型转移性结直肠癌：开放标签Ib/II 期OrigAMI-1 研究结果题目：First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6–Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non–Small Cell Lung Cancer 翻译：靶向整合素 β6 的抗体药物偶联物西戈维妥珠单抗维多汀首个人体Ⅰ 期研究：晚期非小细胞肺癌剂量扩展组结果 LANCET ONCOLOGY 题目：Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial 翻译：阿格拉替马吉恩贝萨腺病毒（CAN-2409）联合放疗治疗局限性前列腺癌：多中心、随机、双盲、安慰剂对照Ⅲ 期试验题目：Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy 翻译：乳腺癌大分割放疗 1 周方案对比3 周方案（FAST-Forward研究）：多中心、开放标签、非劣效性Ⅲ 期随机对照试验的10 年疗效及晚期正常组织损伤结果，以及腋窝亚组随机研究的5 年疗效结果题目：[177Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial 翻译：[¹⁷⁷Lu] 镥- 奥曲肽对比舒尼替尼治疗转移性进展期胰腺神经内分泌肿瘤（OCLURANDOM研究）：随机对照Ⅱ 期试验题目：Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study 翻译：立体定向消融放疗治疗原发性肾癌的长期预后（TROG 15.03 FASTRACK II）：多中心非随机 Ⅱ 期研究题目：Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials 翻译：超大分割立体定向消融放疗治疗原发性肾细胞癌：FASTRACK系列试验汇总分析的5 年随访结果题目：MRI-guided adaptive radiotherapy for high grade glioma (UNITED): a single-centre, single-arm, non-inferiority, phase 2 trial 翻译：磁共振引导自适应放疗治疗高级别胶质瘤（UNITED研究）：单中心、单臂、非劣效性Ⅱ 期试验题目：International disruptions to cancer diagnosis and stage at presentation during the COVID-19 pandemic in 2020: an International Cancer Benchmarking Partnership (ICBP) population-based study 翻译：2020 年新冠疫情期间全球癌症诊断与初诊分期的变化：国际癌症基准联盟基于人群的研究题目：Real-world heart and lung doses from 30 000 National Health Service radiotherapy treatment plans in England: a national audit of breast radiotherapy practice 翻译：英格兰 3 万例国民保健系统放疗计划中心肺实际受照剂量：全国乳腺癌放疗实践审计 JOURNAL OF THORACIC ONCOLOGY 题目：Clinical Value of Combining Molecular and Immune Blood Tests to Safely Reduce False Positives in Low-Dose Computed Tomography Lung Cancer Screening 翻译：联合分子与免疫血液检测降低低剂量 CT 肺癌筛查假阳性率的临床价值题目：Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed Plasma ctDNA Assay 翻译：依托肿瘤溯源型血浆循环肿瘤 DNA 检测识别高风险Ⅰ 期非小细胞肺癌患者题目：Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs 翻译：HER2 突变非小细胞肺癌对德曲妥珠单抗的耐药机制：载荷药物敏感性下降及其他通路改变，及其对后续HER2 酪氨酸激酶抑制剂疗效的影响题目：Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Nonsquamous NSCLC Treated With Chemoradiation and Immunotherapy 翻译：KRAS 突变及共突变对接受放化疗联合免疫治疗的Ⅲ 期非鳞非小细胞肺癌患者预后的影响题目：Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 “DICIPLE” Phase III Trial 翻译：晚期非小细胞肺癌一线纳武利尤单抗联合伊匹木单抗治疗6 个月与持续用药的4 年随访结果：Ⅲ期随机IFCT-1701 DICIPLE 试验题目：Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial 翻译：局限期小细胞肺癌同步放化疗后采用度伐利尤单抗巩固治疗与安慰剂对比的患者报告结局：Ⅲ期ADRIATIC 试验结果 JAMA ONCOLOGY（本周无更新） CANCER RESEARCH 题目：Dynamic Reprogramming of PDGFRA-Expressing Stromal Cells Facilitates WNT-Driven Transformation by Promoting a Fetal-Like State in the Intestinal Epithelium 翻译：表达PDGFRA的基质细胞发生动态重编程，通过诱导肠道上皮呈现胎儿样状态，促进WNT 通路驱动的细胞恶性转化题目：RHOV Is a Detachment-Responsive Rho GTPase Necessary for Ovarian Cancer Peritoneal Metastasis 翻译：RHOV是一种响应细胞脱离状态的Rho 鸟苷三磷酸酶，为卵巢癌腹膜转移所必需题目：Ribonuclease 5/Angiogenin Suppresses Intestinal Tumor Initiation by Maintaining Crypt Homeostasis 翻译：核糖核酸酶 5 / 血管生成素通过维持肠道隐窝稳态，抑制肠道肿瘤发生题目：FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy 翻译：FET 融合癌蛋白扰乱正常DNA 修复过程，为ATR 抑制剂治疗提供可靶向的作用靶点题目：Hyperplasia Functions as a Link between Obesity and Cancer 翻译：组织增生是连接肥胖与肿瘤发生的中间环节题目：Engineering T Cells with a Tumor-Reactive Chimeric T-cell Receptor Reduces Exhaustion and Promotes Persistence to Elicit Enhanced Antitumor Responses 翻译：改造表达肿瘤反应性嵌合 T 细胞受体的T 细胞，可减轻细胞耗竭、提升存续能力，进而增强抗肿瘤效应题目：LDHBDeficiency in Fibroblasts Induces Lactate-Mediated Inflammatory Reprogramming That Promotes Breast Cancer Metastasis 翻译：成纤维细胞LDHB缺失会触发乳酸介导的炎症重编程，进而促进乳腺癌转移题目：METTL3 Methylation Induces Decay of Endogenous Retroelement Transcripts to Promote Tumor Immune Evasion 翻译：METTL3介导的甲基化加速内源性逆转录元件转录本降解，助力肿瘤实现免疫逃逸题目：Stress-Induced ADGRL4 Orchestrates Tumor Progression and Metastasis by Inhibiting YAP1 Signaling and Activating Angiogenesis 翻译：应激诱导的ADGRL4通过抑制YAP1 信号通路、激活血管生成，调控肿瘤进展与转移题目：PKM2 Lactylation Promotes Colorectal Cancer Vasculogenic Mimicry and Bevacizumab Resistance by Facilitating FOSL1 Super-enhancer Formation 翻译：PKM2乳酰化修饰促进FOSL1 超级增强子形成，进而推动结直肠癌血管生成拟态及贝伐珠单抗耐药题目：Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence 翻译：靶向非同源末端连接通路可增强 p53 介导的细胞衰老，使MDM2扩增型脂肪肉瘤对多柔比星增敏题目：Metronomic Chemotherapy Induces Metabolic Reprogramming in Cancer Cells That Modulates Mature Regulatory Dendritic Cell Function to Stimulate Antitumor Immunity 翻译：节拍化疗诱导肿瘤细胞代谢重编程，调控成熟调节性树突状细胞功能，激活抗肿瘤免疫题目：Cancer Susceptibility to Stapled Oncolytic Peptides Is Dictated by Membrane Cholesterol and Inflammatory Signaling 翻译：细胞膜胆固醇与炎症信号通路决定肿瘤细胞对钉合溶瘤肽的敏感性 CLINICAL CANCER RESEARCH 题目：Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer 翻译：FLAURA2 研究患者报告结局：奥希替尼联合/ 不联合化疗用于初治EGFR 突变晚期非小细胞肺癌题目：Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma 翻译：表柔比星、异环磷酰胺联合纳武利尤单抗一线治疗未分化多形性肉瘤的安全性与疗效题目：CCL3+Neutrophil Signature Predicts Response to Neoadjuvant Toripalimab plus Chemotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Phase II Trial 翻译：CCL3⁺中性粒细胞特征可预测下咽鳞癌患者对特瑞普利单抗联合新辅助化疗的应答：一项Ⅱ 期试验题目：Preexisting TCR Clones Drive Major Pathologic Responses in Patients with HNSCC Treated with Dual Immune Checkpoint Inhibitors 翻译：头颈部鳞状细胞癌患者接受双免疫检查点抑制剂治疗时，原有T 细胞受体克隆可介导显著病理缓解题目：Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors 翻译：聚乙二醇脂质体多柔比星治疗晚期难治性硬纤维瘤的Ⅲ 期临床试验题目：A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma 翻译：艾立布林治疗转移性血管肉瘤及上皮样血管内皮瘤的Ⅱ 期研究题目：Locus-Specific Human Endogenous Retrovirus ERVK18 Expression Indicates an Inflamed Microenvironment and Favorable Immunotherapy Outcome in Small Cell Lung Cancer 翻译：人内源性逆转录病毒 ERVK18 位点特异性表达提示小细胞肺癌微环境呈炎症状态，且患者更易从免疫治疗中获益题目：Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial 翻译：基于 Ⅲ 期临床试验数据，构建胶质母细胞瘤发病部位、治疗方案、预后因素与生存期交互作用的统计参数映射分析框架题目：Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study 翻译：H3 G34 突变型弥漫性大脑半球胶质瘤的临床结局与预后特征：一项国际多中心研究题目：Nonmetastatic Para-aortic Lymph Node Remodeling as a Predictor of Outcome in Locally Advanced Cervical Cancer 翻译：非转移性腹主动脉旁淋巴结重塑可作为局部晚期宫颈癌的预后预测指标题目：Association of Tumor-Infiltrating Lymphocyte Subtypes with Clinical Characteristics and Prognosis in Young Women with Hormone Receptor–Positive Breast Cancer 翻译：年轻女性激素受体阳性乳腺癌中，肿瘤浸润淋巴细胞亚型与临床特征及预后的相关性题目：Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition 翻译：采用纵向通路抑制策略逆转胰腺癌对 KRASG12D靶向治疗的获得性耐药题目：Molecular Characterization of KLK2 RNA Expression in Prostate Cancer 翻译：前列腺癌中KLK2 RNA 表达的分子特征分析题目：Ionizing Radiation Enhances Prognostically Significant Cellular Immunity Programs in the Brain Metastasis Microenvironment 翻译：电离辐射可激活脑转移微环境中具有预后价值的细胞免疫通路 JOURNAL OF THE NATIONAL CANCER CENTER（本周无更新） JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE（本周无更新） 3.内分泌学与代谢 LANCET DIABETES & ENDOCRINOLOGY（本周无更新） DIABETES CARE（本周无更新） 4.心血管病学 CIRCULATION 题目：Adaptive AI for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the ODYSSEY OUTCOMES and EUCLID Trials 翻译：自适应人工智能用于心血管事件判定：基于ODYSSEY OUTCOMES 与 EUCLID 试验，对比不同判定标准下的心血管事件评估结果题目：Role of Atrial Pacing Support in Cardiac Resynchronization Therapy: A Noninferiority Randomized Trial 翻译：心房起搏支持在心脏再同步化治疗中的作用：一项非劣效性随机对照试验题目：WNT5a-Mediated Aberrant Actin Filament Dynamics Drive Cardiac Pathogenic Phenotypes in LMNA-Related Emery-Dreifuss Muscular Dystrophy 翻译：WNT5a 介导的肌动蛋白丝动态异常，诱发LMNA相关埃默里- 德赖弗斯肌营养不良的心脏病变表型题目：Defective Trophoblast Differentiation, Endothelial Dysfunction, and Immune Dysregulation in Preeclampsia Coalesce on a Placental VGLL3-Centered Gene Network 翻译：子痫前期存在滋养层分化异常、内皮功能障碍及免疫紊乱，上述病变共同汇聚于以胎盘VGLL3 为核心的基因调控网络 EUROPEAN HEART JOURNAL 题目：Atlas of interventional cardiology 2023: European Society of Cardiology and European Association of Percutaneous Coronary Interventions 翻译：2023 年介入心脏病学图谱：欧洲心脏病学会、欧洲经皮冠状动脉介入治疗协会联合发布题目：Diabetes and sudden cardiac death: a Danish nationwide study 翻译：糖尿病与心源性猝死：丹麦全国性研究题目：Transgender persons receiving gender-affirming hormone therapy: risk of acute cardiovascular events in a Dutch cohort study 翻译：接受性别肯定激素治疗的跨性别人群急性心血管事件风险：荷兰队列研究题目：Long-term exposure to wildfire smoke particulate matter and incident stroke: a US nationwide study 翻译：长期暴露于野火烟雾颗粒物与新发脑卒中：美国全国性研究题目：Frailty and long-term outcomes in younger patients with acute myocardial infarction 翻译：衰弱状态与年轻急性心肌梗死患者的远期预后 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 题目：Emulated Effects of Glucagon-Like Peptide 1 Receptor Agonist Therapy in the General Population 翻译：胰高糖素样肽 1 受体激动剂在普通人群中的模拟干预效应研究题目：Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus 翻译：胰高糖素样肽 1 受体激动剂与钠- 葡萄糖协同转运蛋白2 抑制剂对糖尿病患者心血管获益的对比研究题目：Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure: A Mendelian Randomization Study 翻译：体重指数与心力衰竭患者临床结局及全因死亡的关联：一项孟德尔随机化研究题目：Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses 翻译：司美格鲁肽对合并慢性肾脏病的糖尿病患者肾脏及生存获益：FLOW试验心血管亚组分析题目：Obesity-Associated Cardiovascular Risk and Benefit From PCSK9 Inhibition: A Prespecified Analysis From FOURIER 翻译：肥胖相关心血管风险与 PCSK9 抑制剂的治疗获益：FOURIER试验预设分析 5.胃肠肝病学 LANCET GASTROENTEROLOGY & HEPATOLOGY（本周无更新） JOURNAL OF HEPATOLOGY（本周无更新） GUT 题目：Chronic kidney disease in cirrhosis: a study of inpatients from a global perspective 翻译：肝硬化合并慢性肾脏病：一项全球住院患者研究题目：Luminal–basal stratification of the native human pancreatic duct is differentially represented in pancreatic cancers 翻译：人正常胰腺导管的腔面 - 基部分层特征在不同胰腺癌中存在差异表达题目：TNF-α drives pancreatic microcirculatory dysfunction via CD8+ T cell-mediated endothelial injury in severe acute pancreatitis 翻译：重症急性胰腺炎中，肿瘤坏死因子 -α 通过CD8⁺T 细胞介导内皮损伤，引发胰腺微循环障碍题目：Recent advances in our understanding of the gut microbiome: an analysis from the Gut Microbiota for Health Expert Panel of the British Society of Gastroenterology 翻译：肠道微生物组研究新进展：英国胃肠病学会肠道微生物健康专家小组综述题目：Fusobacterium nucleatumin cancer: from bystander to driver 翻译：具核梭杆菌与肿瘤：从旁观者转变为致病驱动因子 GASTROENTEROLOGY（本周无更新） 6.呼吸病学 LANCET RESPIRATORY MEDICINE 题目：Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial 翻译：特泽佩鲁单抗对比安慰剂减少重度口服激素依赖性哮喘成人患者激素用量的疗效与安全性（SUNRISE）：多中心、安慰剂对照、双盲Ⅲ 期试验题目：Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort study 翻译：天青杀素 - 1 作为支气管扩张症严重程度、上皮防御功能的调控因子及二肽基肽酶- 1 抑制剂作用靶点：一项国际多队列研究题目：PET–CT benchmarked detection and 5-year progression of asymptomatic tuberculosis: a longitudinal, prospective cohort study 翻译：基于 PET-CT 评估无症状肺结核的检出及5 年病情进展：前瞻性纵向队列研究题目：Whole genome sequencing precision medicine strategy to shorten treatment for rifampicin-resistant tuberculosis (SMARTT): a pragmatic, randomised, single-blind phase 4 trial 翻译：全基因组测序精准医疗方案缩短利福平耐药肺结核疗程（SMARTT）：实用性随机单盲Ⅳ 期试验题目：Non-invasive respiratory supports and criteria for intubation in randomised trials of acute hypoxaemic respiratory failure: a systematic review and network meta-analysis 翻译：急性低氧性呼吸衰竭随机试验中的无创呼吸支持方式与气管插管指征：系统综述及网状Meta 分析 EUROPEAN RESPIRATORY JOURNAL 题目：Pathophysiology and prevalence of high output heart failure in group 1 pulmonary hypertension 翻译：第一大类肺动脉高压合并高输出量心力衰竭的病理生理机制与患病率题目：Pulmonary hypertension in patients with Noonan syndrome 翻译：努南综合征患者合并肺动脉高压的相关研究题目：sST2 and IL-6 predict prognosis of medically treated chronic thromboembolic pulmonary hypertension 翻译：可溶性 ST2 与白介素- 6 可预测药物治疗的慢性血栓栓塞性肺动脉高压患者预后题目：Saline lavage alone prolongs drainage compared with intrapleural enzyme therapy in pleural infection: the SCOPE randomised controlled trial 翻译：胸腔感染治疗中，单纯生理盐水灌洗相比胸腔内酶疗法可延长引流时长：SCOPE随机对照试验题目：Tidal breathing nasal nitric oxide measurement as a test for primary ciliary dyskinesia in young children 翻译：潮气呼吸下鼻一氧化氮检测用于幼儿原发性纤毛运动障碍的筛查 7.感染与微生物 LANCET INFECTIOUS DISEASES（本周无更新） LANCET MICROBE（本周无更新） NATURE MICROBIOLOGY 题目：IL-22 promotes genesis of small intestinal secretory cells that protect against cholera in mice 翻译：白介素 - 22 可促进小鼠小肠分泌细胞生成，进而抵御霍乱感染题目：Functional diversity of phage sponge proteins that sequester host immune signals 翻译：截留宿主免疫信号的噬菌体海绵蛋白具有功能多样性题目：Engineered Bacteroides thetaiotaomicron sense gut inflammation and deliver therapeutic molecules to alleviate colitis in mice 翻译：工程化多形拟杆菌可感知肠道炎症，并释放治疗分子以缓解小鼠结肠炎 MICROBIOME 题目：Aging of the adaptive immune system affects the gut microbiome and systemic levels of vitamin B6 翻译：适应性免疫系统衰老对肠道微生物组及机体维生素B6 整体水平的影响题目：The Iceman’s microbiome: unveiling millennia of microbial diversity and continuity 翻译：冰人微生物组：揭秘千年以来微生物的多样性与种群延续性题目：mPower: a real data-based power analysis tool for microbiome study design 翻译：mPower：基于真实数据的微生物组研究设计效能分析工具题目：Host-guided microbiome-metabolite interactions enable cross-kingdom SynComs for disease suppression 翻译：宿主介导的微生物组 - 代谢物互作，助力构建跨界合成菌群以抑制疾病题目：Multi-omics characterization of the skin microbiota reveals the anti-aging roles of Stenotrophomonas maltophilia 翻译：皮肤微生物组的多组学分析揭示嗜麦芽窄食单胞菌的抗衰老作用题目：Ecological and metabolic restructuring of anaerobic microbiomes under sulfate stress via magnetite-enhanced cooperative networks 翻译：磁铁矿强化菌群协作网络，推动硫酸盐胁迫下厌氧微生物组发生生态与代谢重塑 JOURNAL OF INFECTION（本周无更新） 8.公共卫生和流行病学 LANCET PUBLIC HEALTH（本周无更新） LANCET GLOBAL HEALTH（本周无更新） 9.内科学 JAMA INTERNAL MEDICINE 题目：Fecal Microbiota Transplant and Multidrug-Resistant Organism Decolonization in Gastrointestinal Disease: A Randomized Clinical Trial 翻译：粪便微生物群移植用于胃肠道疾病患者多重耐药菌清除：一项随机临床试验题目：Deprescribing Intervention and Reduction of Proton Pump Inhibitor Use in Primary Care: A Cluster Randomized Clinical Trial 翻译：基层医疗机构开展停药干预以减少质子泵抑制剂使用：整群随机临床试验题目：Palliative Care Intervention for Patients With End-Stage Liver Disease: A Cluster Randomized Clinical Trial 翻译：终末期肝病患者姑息治疗干预研究：整群随机临床试验题目：Benefits and Harms of Dementia Screening for Family Members of Older Adults: A Randomized Clinical Trial 翻译：针对老年人家属开展痴呆筛查的获益与风险：一项随机临床试验题目：Mailed Outreach for Colorectal Cancer Screening in Community Health Centers: The CARES Pragmatic Cluster Randomized Clinical Trial 翻译：社区卫生中心依托邮件推送开展结直肠癌筛查：CARES实用性整群随机临床试验题目：Prompt and Intensive Antiviral Chemoprophylaxis in Nursing Home Influenza Outbreaks 翻译：养老院流感暴发时开展早期强化抗病毒药物预防题目：Out-of-Pocket Spending for Insulin by Medicare Beneficiaries After Monthly Caps 翻译：实施月费用上限政策后，联邦医疗保险参保者的胰岛素自付费用变化题目：The Oncology Care Model and Initiation of Systemic Therapy for Cancer 翻译：肿瘤医疗照护模式与肿瘤全身治疗启动情况分析 ANNALS OF INTERNAL MEDICINE（本周无更新） 10.血液学 LANCET HAEMATOLOGY 题目：Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial 翻译：复发 / 难治性急性白血病造血干细胞移植前采用全骨髓及淋巴组织放疗联合环磷酰胺、依托泊苷预处理：单中心、开放标签Ⅱ 期试验题目：Diagnosis of primary CNS lymphoma through molecular and immune biomarkers in cerebrospinal fluid (PRICELUS): a multicentre, prospective, cohort study 翻译：基于脑脊液分子及免疫生物标志物诊断原发性中枢神经系统淋巴瘤（PRICELUS）：多中心前瞻性队列研究题目：Post pulmonary embolism syndrome following paediatric pulmonary embolism: a multicentre, retrospective cohort study 翻译：儿童肺栓塞后综合征研究：多中心回顾性队列研究题目：Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study 翻译：基于血常规检测预测骨髓增殖性肿瘤患者骨髓纤维化（FIBOM-AI）：多中心机器学习模型构建与验证研究 11.牙科与口腔外科 JOURNAL OF CLINICAL PERIODONTOLOGY（本周无更新）

100 项与 Aglatimagene besadenovec 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15074

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非鳞状非小细胞肺癌	临床3期	美国	Candel Therapeutics, Inc.	2026-06-15
局限性前列腺癌	临床3期	美国	Candel Therapeutics, Inc.	2011-09-01
前列腺腺癌	临床2期	美国	Candel Therapeutics, Inc.	2025-10-30
转移性非小细胞肺癌	临床2期	美国	Candel Therapeutics, Inc.	2020-10-13
转移性非小细胞肺癌	临床2期	美国	NYU Langone Health	2020-10-13
非小细胞肺癌	临床2期	美国	Candel Therapeutics, Inc.	2020-10-13
前列腺癌	临床2期	美国	Candel Therapeutics, Inc.	2016-05-01
前列腺癌	临床2期	墨西哥	Candel Therapeutics, Inc.	2016-05-01
复发性前列腺癌	临床2期	美国	Candel Therapeutics, Inc.	2016-05-01
复发性前列腺癌	临床2期	墨西哥	Candel Therapeutics, Inc.	2016-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01436968 (ASTRO2025 \| Company_Website) 人工标引	临床3期	局限性前列腺癌	745	CAN-2409 + prodrug + EBRT ± ADT	積鏇獵鹹餘積鑰製蓋蓋(艱築鑰選憲壓遞繭鹽糧) = CAN-2409 improved DFS in important subgroups, including hypo- or standard fractionated EBRT, with or without ADT. 積襯獵獵繭範艱積糧鹹 (廠膚醖廠膚鏇獵鏇鑰膚 ) 更多	积极	2025-09-28
				Placebo + prodrug + EBRT ± ADT
NCT01436968 (Phase 3, ASCO2025)	临床3期	局限性前列腺癌	745	CAN-2409+prodrug	獵鬱簾構廠積遞窪鏇膚(淵選鑰膚餘膚鬱廠繭積) = 構衊襯積鏇繭顧簾積醖艱膚觸糧觸簾窪淵醖夢 (觸鏇壓獵網衊壓衊築醖 )	积极	2025-05-30
				Placebo+prodrug	獵鬱簾構廠積遞窪鏇膚(淵選鑰膚餘膚鬱廠繭積) = 憲鏇膚遞繭壓鏇鑰壓鬱艱膚觸糧觸簾窪淵醖夢 (觸鏇壓獵網衊壓衊築醖 )
NCT04495153 (GlobeNewswire) 人工标引	临床2期	晚期非小细胞肺癌	46	CAN-2409 (cohort 1 and 2)	鹽襯衊觸選繭蓋齋壓築(齋鏇鹽糧醖積廠糧構觸) = 積窪膚築鑰蓋齋廠夢夢糧衊選餘遞選築積淵鹽 (蓋簾窪鹽鹹獵醖網構選 )	积极	2025-03-26
				CAN-2409 (cohort 2)	鹽襯衊觸選繭蓋齋壓築(齋鏇鹽糧醖積廠糧構觸) = 鬱構鬱憲壓繭構遞構衊糧衊選餘遞選築積淵鹽 (蓋簾窪鹽鹹獵醖網構選 )
NCT02446093 (PaTK02, Company_Website) 人工标引	临床2期	胰腺癌新辅助	13	CAN-2409 + valacyclovir + SoC	選遞構選廠艱窪蓋壓餘(鹹鑰鏇糧膚構淵鹽壓齋) = 範齋獵襯廠廠壓壓鑰鏇鹹製窪窪淵糧選廠糧獵 (廠膚衊繭積構壓餘齋夢 ) 更多	积极	2025-02-25
				SoC	選遞構選廠艱窪蓋壓餘(鹹鑰鏇糧膚構淵鹽壓齋) = 構積窪衊夢窪遞壓範網鹹製窪窪淵糧選廠糧獵 (廠膚衊繭積構壓餘齋夢 ) 更多
NCT01436968 (PipelineReview) 人工标引	临床3期	前列腺癌	745	CAN-2409 plus Standard of care external beam radiation therapy	襯醖淵窪鑰餘觸艱選製(糧顧餘鹽蓋壓範範夢網): HR = 0.7, P-Value = 0.0155 达到更多	积极	2024-12-11
				Standard of care external beam radiation therapy
NCT04495153 (ASCO2024) 人工标引	临床2期	非小细胞肺癌	73	CAN-2409 + valacyclovir	夢構製窪獵齋襯齋膚艱(鏇獵鹽襯壓遞築鬱糧窪) = 範獵簾憲窪範鑰鹽鏇鑰夢積遞簾範衊餘糧簾顧 (膚製築醖窪獵積鹹網憲, 14.3 ~ NA) 更多	积极	2024-05-24
				CAN-2409 + valacyclovir (C1, stable disease)	夢構製窪獵齋襯齋膚艱(鏇獵鹽襯壓遞築鬱糧窪) = 範築鬱膚願艱願遞壓築夢積遞簾範衊餘糧簾顧 (膚製築醖窪獵積鹹網憲 )
NCT02446093 (PaTK02, Biospace) 人工标引	临床2期	胰腺癌	13	CAN-2409+valacylovir or acyclovir+chemoradiation or SBRT	顧鏇艱簾鏇選鬱憲獵憲(鏇選襯齋範選選蓋醖鏇) = none 糧襯鹹膚鹽選壓鑰醖壓 (壓廠壓憲醖遞願觸獵壓 )	积极	2024-04-04
				chemoradiation or SBRT
NCT00589875 (BrTK02, CTgov)	临床2期	多形性胶质母细胞瘤 \| 高级别胶质瘤	52	Radiation therapy+Temozolomide+Valacyclovir+CAN-2409	艱廠艱餘鹹衊鏇蓋願選 = 鑰憲繭製廠選繭願鹹築齋觸鹹積憲憲積鏇網範 (鏇蓋糧夢壓襯淵鏇膚窪, 遞鹽積積觸選醖範壓夢 ~ 構鑰築廠顧鏇膚淵鑰壓) 更多	-	2024-04-03
NCT02768363 (ULYSSES, Corporate Publications)	临床2期	前列腺癌一线	-	Aglatimagene besadenovec	築選鹹遞鬱製鏇鏇夢範(觸窪範襯鹹糧鹹鑰選繭) = 觸繭齋構網廠蓋積蓋製鏇製淵願顧艱齋艱膚壓 (餘鏇齋窪蓋鹽鏇襯窪網 ) 更多	积极	2024-01-01
				control populations	築選鹹遞鬱製鏇鏇夢範(觸窪範襯鹹糧鹹鑰選繭) = 鑰網遞簾餘構齋製淵鏇鏇製淵願顧艱齋艱膚壓 (餘鏇齋窪蓋鹽鏇襯窪網 ) 更多
NCT02446093 (PaTK02, SITC2023)	临床2期	局部晚期胰腺腺癌新辅助 soluble granzymes B \| IL-10 \| IFNÎ³	19	CAN-2409+prodrug	壓醖鹹構壓餘網鹹淵簾(齋憲糧艱廠鏇膚憲鑰繭) = 積齋窪網鏇蓋鏇齋鬱夢醖餘簾觸蓋顧餘選憲選 (鑰糧衊範艱餘築憲艱觸 ) 更多	积极	2023-11-02
				CAN-2409+Prodrug (Standard of care (SOC) chemoradiation (CR) and surgery)	壓醖鹹構壓餘網鹹淵簾(齋憲糧艱廠鏇膚憲鑰繭) = 蓋窪醖夢獵願醖遞壓糧醖餘簾觸蓋顧餘選憲選 (鑰糧衊範艱餘築憲艱觸 ) 更多